

NZX/ASX Announcement

13 December 2023

TruScreen included on the Vietnamese Ministry Of Health Approved Technical List Highlights:

- TruScreen included on the Vietnamese Ministry of Health approved Technical List
- The Technical Listing will simplify and shorten the procurement process for public hospitals.
- The Technical Listing will enable nationwide adoption of TruScreen in the public healthcare sector.

TruScreen Group Limited (NZX/ASX:TRU) is pleased to advise that it has been included in the Vietnamese Ministry Of Health (MOH) approved Technical List. This significant milestone enables TruScreen to be used nationally from top level hospitals to community health centres. The listing reduces the need for individual hospitals to seek prior approval thereby shortening dramatically the procurement process.

The MOH recognised the value of the Truescreen technology in accelerating the cervical cancer screening at lower public healthcare costs with greater innovative patient-focused approach. The listing by the MOH was based on extensive clinical evidence supporting TruScreen, positive feedback from local users at several levels of the public healthcare providers, including leading gynaecological hospital, Hanoi Obstetrics and Gynaecology Hospital.

The Inclusion in the approved Technical List will allow our distributor Gorton Health Services (GHS) to expand distribution of the TruScreen Al-enable technology in Vietnam.

CEO, Dr Beata Edling said:

"We are delighted that the Ministry of Health in Vietnam has approved TruScreen as the technology that will assist Vietnam in achieving the World Health Organisation targets in cervical cancer screening. The work of our partner in Vietnam, GHS, has prepared Truscreen for an accelerated national uptake. We congratulate GHS on their efforts and look forward to this new phase of growth development".

This announcement has been approved by the Board.

Ends



For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson Chief Financial Officer guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.


TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In financial year 2023 alone, over 140000* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.

Glossary:



Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/paptest

LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test https://www.cancer.net/cancer-types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention

Sensitivity and **specificity** mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, <u>conditioned</u> on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative (<u>Sensitivity and specificity Wikipedia</u>).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)

Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council